morphine/naltrexone (Embeda)
Jump to navigation
Jump to search
Introduction
Capsules containing extended-release morphine pellets with an inner core of the opioid antagonist naltrexone
Indications
- analgesia for patients at risk of substance abuse
- prevents one type of abuse, crushing the capsule to get all the morphine as immediate release
Dosage
- morphine 20 mg & naltrexone 0.8 mg
- morphine 30 mg & naltrexone 1.2 mg
- morphine 50 mg & naltrexone 2 mg
- morphine 60 mg & naltrexone 2.4 mg
- morphine 80 mg & naltrexone 3.2 mg
- morphine 100 mg & naltrexone 4 mg
Pharmacokinetics
- swallowing the capsules whole slowly releases just the morphine, but if the pellets are crushed, the naltrexone is released & can blunt morphine's effects
Adverse effects
- constipation (31%)
- nausea (22%)
- vomiting (8%)
- sleepiness (7%)
- headache (7%)
- itching (6%)
- dizziness (4%)
- fatigue (4%)
Drug interactions
- see morphine
Notes
costs $250 to $850 for 60 caps (2009)
More general terms
References
- ↑ Prescriber's Letter 16(10): 2009 New Drug: Embeda (Morphine/Naltrexone) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251009&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA News Release. October 17, 2014 FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm419288.htm
- ↑ EMBEDA Prescribing Information http://labeling.pfizer.com/ShowLabeling.aspx?id=694